Corbus Pharmaceuticals announced that it has completed enrollment of the dose escalation part of its bridging Phase 1 clinical trial of CRB-701. The dose escalation part of this open label study is being conducted in the US and the UK. The three-part Phase 1 trial is evaluating the safety, pharmacokinetics and efficacy of CRB-701 in patients with advanced solid tumors associated with high Nectin-4 expression. The Part A dose escalation of the Phase 1 study is evaluating four predetermined doses and will be followed by Part B and Part C that will determine recommended/optimized doses and seek preliminary efficacy signals.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBP:
- Largest borrow rate increases among liquid names
- Biotech Alert: Searches spiking for these stocks today
- Corbus Pharmaceuticals price target lowered to $40 from $85 at B. Riley
- Corbus price target lowered to $51 from $85 at Wedbush after Novo data
- Corbus sinks 61% to $20 after Novo Nordisk weight loss data